In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Les Laboratoires Servier

http://www.servier.com/

Latest From Les Laboratoires Servier

ASCO Preview: Five Top Late-Breakers To Watch For

AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.

ASCO Cancer

Double Whammy For Merck And Eisai’s Keytruda/Lenvima Combo In Solid Tumors

The partners’ combination of Keytruda and Lenvima has missed the mark in two pivotal trials in melanoma and colorectal cancer, leading to one trial discontinuation and dashing hopes for important label expansions.

Clinical Trials ImmunoOncology

InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody

The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.

Approvals Coronavirus COVID-19

Servier’s Oncology Strategy Pays Off As Vorasidenib Hits Bullseye In Pivotal Glioma Trial

The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Biogaran SAS
    • Egis Pharmaceuticals plc
    • WeHealth
    • Servier BioInnovation
    • Symphogen A/S
    • Servier Pharmaceuticals, LLC.
UsernamePublicRestriction

Register